analyze neuronal function and identify disease-relevant phenotypes. The company uses these data-driven methods to discover and validate therapeutic targets, as well as to design and optimize candidate molecules for neurological and neurodevelopmental conditions. It maintains a pipeline that includes programs for chronic pain, seizure disorders, and genetic neurological diseases, progressing candidates from early discovery through preclinical and clinical stages. The organization also collaborates with external partners and applies its platform to improve prediction of drug efficacy and safety in the development of treatments for brain-related diseases.